Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

IT and FMCG stocks lead the rally
Thu, 31 Mar 01:30 pm

After trading firm during the previous two hours of trade Indian stock market indices have extended their gains on the back of strong buying interest across sectors. Stocks from the IT and FMCG space are trading strong while those from the auto space are trading marginally in the red.

Currently, the BSE-Sensex is up by 177 points while NSE-Nifty is trading 45 points above the dotted line. BSE Midcap and BSE Small cap indices are both up by 0.02% and 0.40% respectively. The rupee is trading at 44.64 to the US dollar.

Pharma stocks are trading mixed with Dr Reddy's and Fresenius Kabi leading the gains. However, Orchid Chemicals is trading weak. Dr Reddy's Laboratories Ltd (DRL) has finally completed the acquisition of GlaxoSmithKline's (GSK) oral penicillin facility and product portfolio in the US. It may be noted that the two companies had signed an agreement towards the same on 23 November 2010. After the acquisition DRL now has the ownership for the penicillin manufacturing site in Bristol and Tennessee. It also has the rights for the two brands, Augmentin and Amoxil in the US. However, GSK will retain the rights of these brands outside the US. It may be noted that the financial terms of the said transaction have not been disclosed. The acquisition of GSK brands was done to scale up the generic business of DRL in North America. This is likely to provide additional synergy to the business.

Real estate stocks are trading mixed with Sobha Developers and Atlanta Ltd leading the gains. However, Mahindra Lifespace Developers and Orbit Corporation are trading weak. Amidst fall in volumes real estate companies have started negotiating with banks to postpone their repayment deadlines. It may be noted that the real estate companies have already rescheduled Rs 60 bn worth of loans in the past 3 months. And considering the current market conditions further rescheduling cannot be ruled out. It may be noted that these companies do not have adequate cash flow in order to meet the repayment schedules. And they are not willing to lower the prices of the housing units as well so as to address the liquidity issue. This has led to a series of restructuring in the repayment schedules. Even banks have no viable option but to agree to the new repayment schedule as they do not want their loans to be classified as an NPA . Prominent banks who have a huge real estate loan portfolio include PNB, SBI, Bank of Baroda and OBC.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "IT and FMCG stocks lead the rally". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.